Updated Interim Results Announced From LEGEND Cohort of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC patients with CIS with or without concomitant papillary disease
“These updated data continue to reinforce the favorable safety and tolerability profile of detalimogene and its clinical activity in a heavily pretreated, high-risk NMIBC patient population with limited therapeutic options. Importantly, the low rate of progression to muscle-invasive disease leaves patients eligible for other bladder-sparing therapies,” said Ron Cooper, President and Chief Executive Officer, enGene. “While durability outcomes to date are not what we hoped, these data are preliminary. We are focused on evaluating the totality of the data as it evolves and plan to continue to engage with the FDA and the medical community.”
Share:
More News
Alistair Henry, Executive Vice President & Chief Scientific Officer at UCB said, “Partnering with CRUK’s Centre for Drug Development and Cancer Research Horizons allows us to harness their world-class oncology expertise and clinical insights, complementing UCB’s strengths in discovery and development. This collaboration is a testament to the power of
“We are excited to write the next chapter of Cytospire’s story with this fantastic group of specialist investors,” said Natalie Mount, Chief Executive Officer of Cytospire Therapeutics. “Immune cell engagers are an important type of cancer immunotherapy, but we know that there are significant limitations from both an efficacy and
“This financing represents an important milestone for Signadori Bio as we continue to build on our promising preclinical data and advance our platform toward the clinic. Our approach to in vivo engineering of monocytes has the potential to unlock a new class of immunotherapies that are more accessible, scalable, and
“We are thrilled to have the support of top-tier investors who believe in inobrodib’s potential to address a critical need in multiple myeloma, notably after bispecific T cell engager or anti-BCMA therapies. This is a significant and growing unmet need,” said Will West, Ph.D., CEO of CellCentric. “Inobrodib is a